Eli Lilly goes big on AI-generated drug discovery

Photo: Eli Lilly & Company – February 16, 2011. Photo credit: Paul Sableman via Flickr. CC BY 2.0. Article by Holly Van Leuven. Morning Brew – March 30, 2026.

Eli Lilly made a $2.75 billion deal with Hong Kong-based Insilico Medicine, a startup that uses AI to accelerate drug discovery. Under the terms:

• Insilico will receive $115 million up front and can earn the full value of the deal if the drugs it produces and Lilly licenses reach certain regulatory and sales milestones, as well as through royalties.
• Lilly gets the exclusive rights to sell an Insilico-developed GLP-1 drug for diabetes, per the Financial Times. […]

Click here to view original web page at www.morningbrew.com

Related articles:

Eli Lilly expands Insilico pact with $2.75B AI drug discovery deal – TechTarget

Pharma Giant Eli Lilly Is Paying $2.75 Billion for Drugs Designed by AI – Here’s What It Gets Them – Entrepreneur

Eli Lilly extends partnership with Insilico Medicine for AI-powered drug discovery – Reuters